# Alvotech > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alvotech). ## Overview Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines. Its business combines biosimilar research and development, regulatory approval activities, and commercial supply through partnerships in key markets, with operations spanning multiple regions. ## Products & services • Biosimilar medicine development • Biosimilar manufacturing and supply • Regulatory filing and market authorization support • Partnered commercialization of approved biosimilars • Development of proposed biosimilars to major biologics - **Biosimilar product candidates** (35%) — Development programs for biosimilar versions of branded biologic medicines. - **Commercial biosimilar supply** (45%) — Manufacture and supply of approved biosimilar products to partners and markets. - **Licensing and commercialization rights** (20%) — Upfront, milestone, and ongoing value tied to partnered product rights. - Biosimilar medicine development - Biosimilar manufacturing and supply - Regulatory filing and market authorization support - Partnered commercialization of approved biosimilars - Development of proposed biosimilars to major biologics ## Customers Alvotech sells into a partner-led pharmaceutical commercial model, so its direct customers are primarily licensing and commercialization partners rather than end patients. Those partners include companies that market biosimilars in the U.S. and selected international markets, while healthcare systems and patients are the ultimate end users of the medicines. The company also interacts with regulators and contract manufacturing/commercialization counterparties as part of its product launch model. - **Commercialization partners** (primary) — Pharma partners that license or co-commercialize Alvotech biosimilars in exchange for market access and execution support. - **Regional market partners** (primary) — Local partners that handle regulatory submissions and commercialization in specific countries or regions. - **Healthcare providers and systems** (secondary) — Hospitals, clinics, and payers that use biosimilars because they can lower treatment costs versus branded biologics. - **Patients** (secondary) — Patients receiving biosimilar therapies for oncology, immunology, or rare-disease indications through the healthcare system. - Pharmaceutical commercialization partners - Regional licensees in selected markets - U.S. commercial platform partners - Healthcare systems buying lower-cost biologics - Patients treated with biosimilar medicines ## Geography Alvotech operates on a global basis and reports in U.S. dollars, while its business involves multiple currencies and market regions. The company’s partnerships and commercialization rights extend across the United States and selected Asian markets, and its operating exposure includes Europe, Iceland, the U.K., Switzerland, and other international markets tied to development and supply. Geography matters because regulatory approval, commercial access, and foreign-exchange exposure all vary by market. - **United States** (0%) — No revenue geography split was disclosed in the provided excerpts - **Asia** (0%) — Selected Asian commercialization markets mentioned in the Lotus agreement - **Europe** (0%) — Operating and currency exposure references in disclosures - Global operations with U.S. reporting currency - United States is a core commercialization market - Selected Asian markets are covered by partner rights - Europe and Iceland are important operating locations - Multiple currencies create foreign-exchange exposure ## Strategy Alvotech’s strategy centers on building a biosimilar portfolio, securing regulatory approvals, and expanding commercialization through third-party partners. The company also seeks to capture more value from its development and manufacturing platform through direct participation in U.S. commercialization for selected products and by extending reach into Asia through regional agreements. - **Advance biosimilar pipeline** (medium-term) — A larger approved portfolio is necessary to scale supply, partner value, and future revenue opportunities. - **Partner-led commercialization** (short-term) — The company depends on partners for market access and local execution in markets where it lacks its own commercial infrastructure. - **Broaden geographic reach** (medium-term) — Regional deals diversify access to large markets without requiring full local sales builds. - **Build manufacturing leverage** (medium-term) — Exclusive supply arrangements can convert development success into recurring product supply revenue. - Advance biosimilar candidates through development and approval - Use partners for market access and local commercialization - Increase value capture in the U.S. market - Expand reach into selected Asian markets - Rely on integrated development and manufacturing capabilities ## Risks Alvotech faces the normal risks of a biosimilar developer: clinical and regulatory uncertainty, intense competition, and dependence on partners to commercialize approved products. Its reported accounting weaknesses, judgment-heavy development capitalization, and foreign-currency exposure add operational and reporting risk, while manufacturing and supply execution remain critical to converting approvals into revenue. - **Development and regulatory uncertainty** [high] — Biosimilar programs require successful preclinical, clinical, and regulatory steps before commercialization. - **Partner dependence** [high] — Alvotech relies on third parties for commercialization and market access in many markets. - **Manufacturing and supply chain execution** [high] — The business must reliably supply product after approval, and disruptions can delay revenue and damage partner relationships. - **Competitive pressure** [high] — Biosimilars compete against both branded originators and other biosimilar developers in regulated markets. - **Internal control weaknesses** [medium] — Management disclosed material weaknesses in internal control over financial reporting. - **Foreign exchange volatility** [medium] — The company transacts in multiple currencies while reporting in U.S. dollars. - Biosimilar development can fail or be delayed in trials and approvals - Competition is intense from branded and biosimilar manufacturers - Commercial partners control market access and execution - Manufacturing and supply chain disruptions can block launches - Material weaknesses increase financial reporting control risk - Currency swings affect a multi-currency global business ## Accounting Alvotech’s accounting is shaped by judgment-heavy development capitalization, revenue recognition, and valuation of financing instruments. Investors should watch how the company determines when IAS 38 capitalization begins, how it values derivative liabilities, and how material weaknesses in controls could affect the reliability of reported results. - **Development cost capitalization** — Can materially shift expenses into assets and affect earnings timing - **Revenue recognition** — Affects when collaboration and product revenue is recognized - **Derivative financial liabilities** — Can swing reported finance costs and net results - **Material weaknesses in internal controls** — Affects confidence in reported financial statements - Capitalized development costs depend on IAS 38 feasibility judgments - Revenue recognition can vary by partner terms and milestones - Derivative financial liabilities require recurring fair-value estimates - Deferred tax asset recoverability is judgmental - Material weaknesses raise control and reporting reliability concerns --- *Last updated: 2026-09-28T11:57:40.133912+00:00*